Kiniksa Pharmaceuticals Files 8-K

TL;DR

KINX filed an 8-K, mostly financial docs, no major news.

AI Summary

On March 29, 2024, Kiniksa Pharmaceuticals, Ltd. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.

Why It Matters

This filing indicates routine corporate reporting, likely containing financial statements and exhibits, which are standard for public companies.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any new material risks or significant negative events.

Key Numbers

• 001-38492 — SEC File Number (Identifies the company's filing with the SEC)
• 1231 — Fiscal Year End (Indicates the end of the company's fiscal year)

Key Players & Entities

• Kiniksa Pharmaceuticals, Ltd. (company) — Registrant
• March 29, 2024 (date) — Date of earliest event reported
• 001-38492 (company) — SEC File Number
• Clarendon House (location) — Principal executive offices address
• Lexington, MA (location) — US operational address

FAQ

Key Financial Figures

• $0.000273235 — ich Registered Class A Common Shares $0.000273235 par value KNSA The Nasdaq Stock Mar

Filing Documents

• tm249997d1_8k.htm (8-K) — 38KB
• tm249997d1_ex99-1.htm (EX-99.1) — 62KB
• tm249997d1_ex99-1img001.jpg (GRAPHIC) — 8KB
• 0001104659-24-040847.txt ( ) — 296KB
• knsa-20240329.xsd (EX-101.SCH) — 3KB
• knsa-20240329_lab.xml (EX-101.LAB) — 33KB
• knsa-20240329_pre.xml (EX-101.PRE) — 22KB
• tm249997d1_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. Kiniksa Proposes Redomiciliation from Bermuda to the United Kingdom On March 29, 2024, Kiniksa Pharmaceuticals, Ltd. (the "Company" and, together with its consolidated subsidiaries, "Kiniksa") announced that it intends to change the place of incorporation of Kiniksa's principal holding company from Bermuda to the United Kingdom (the "Redomiciliation"). Subject to the approval of a scheme of arrangement (the "Scheme") by the Company's shareholders and the Supreme Court of Bermuda, the Redomiciliation will result in the creation of a newly formed public holding company which will be organized in the United Kingdom ("New Kiniksa"). Pursuant to the Scheme, the Company's issued and outstanding common shares will be cancelled and Company shareholders will receive new shares from New Kiniksa on a one-for-one basis. Kiniksa has determined that Bermuda is no longer the most desirable jurisdiction for Kiniksa's principal holding company's place of incorporation and believes that redomiciling Kiniksa's principal holding company from Bermuda to a country with a more expansive tax treaty with the United States would be in the best interests of shareholders, employees and other stakeholders. Kiniksa believes that moving the place of incorporation of its principal holding company to the United Kingdom by way of the Redomiciliation is the best available option. Kiniksa does not expect the Redomiciliation will have any material impact on its financial results. Kiniksa would continue be subject to the same reporting obligations with the U.S. Securities and Exchange Commission. New Kiniksa's Class A ordinary shares would be expected to continue to trade on the Nasdaq Global Select Market under the ticker symbol "KNSA". Full details of the proposed Redomiciliation, and the associated benefits and risks, will be provided to shareholders in a proxy statement with respect to a shareholders' meeting. If approved, the Company expects to complete the Redomicili

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. All statements other than statements of historical facts contained in this Current Report on Form 8-K including statements with respect to the business of Kiniksa and Kiniksa's intention to change the place of incorporation of its principal holding company from Bermuda to the United Kingdom (the "Redomiciliation") are forward-looking statements. I n some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "goal," "design," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Current Report on Form 8-K are only predictions. We have based these forward-looking statements largely on our current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results , performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: our ability to obtain the approval of Kiniksa shareholders for the Redomiciliation and the resolutions proposed at related meetings of our shareholders, our ability to satisfy the other conditions to the Redomiciliation on the expected timeframe, or at all, our ability to realize the expected benefits from the Redomiciliation and the occurrence of unanticipated difficulties or costs in connection with the Redomiciliation. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the caption "Risk Factors" contain

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Practice Statement Letter dated as of March 29, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS, LTD. Date: March 29, 2024 /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary